Trial Profile

Phase I/II Study of Dasatinib and Osimertinib (AZD9291) in Patients With Advanced Non-small Cell Lung Cancer With EGFR Mutations

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 17 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dasatinib (Primary) ; Osimertinib (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

05 Jul 2024 Status changed from active, no longer recruiting to discontinued.
09 Jan 2022 Planned End Date changed from 1 Nov 2021 to 1 Jun 2023.
09 Jan 2022 Planned primary completion date changed from 1 Sep 2021 to 1 Jun 2022.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com